Project Grant R21AI203622
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $242K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $441,100 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research targeting phosphoglucomutase in Pneumocystis pneumonia. The research addresses the glucan-rich cell wall of Pneumocystis, which synthesizes β-glucans from uridine diphosphate glucose, a pathway requiring phosphoglucomutase (PGM) to interconvert glucose-6-phosphate and glucose-1-phosphate. Prior...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Rochester $634,882 on August 19, 2026, as a Project Grant (R01AI201741) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into immunomodulation for treatment and prophylaxis of Pneumocystis pneumonia (PCP), a life-threatening fungal infection prevalent in immunocompromised...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $443,850 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how intestinal exposure to Candida albicans in early life influences developing immune responses, specifically T cell responses and the differentiation of T helper 17 cells that produce the inflammatory cytokine IL-17. The research addresses the growing epidemic of immune-mediated diseases in...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $795,316 on July 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on induced pluripotent stem cell (iPSC) reprogramming using a measles virus vector system. The research focuses on developing and characterizing a single-cycle measles virus (MEV) vector that expresses four reprogramming factors in one genome to generate iPSCs from human fibroblasts with improved...
- Federal Project Grant Award Summary Mayo Clinic Arizona, a nonprofit academic medical center and research institution, received a $486,109 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective July 1, 2025, through June 30, 2027, supports investigator-initiated biomedical research examining Type 2 immune responses in endotoxemia-induced lung injury. The research project...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $452,375 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify transcription factors that promote pulmonary infection by opportunistic pathogens. The recipient will conduct research to determine how the transcription factor RpoN responds to environmental signals in Pseudomonas aeruginosa and Klebsiella pneumoniae, and how...
- The National Institute of Allergy and Infectious Diseases awarded Albany Medical College $604,681 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular and epigenetic mechanisms of endothelial inflammatory memory in sepsis survivors vulnerable to secondary infections, particularly pneumonia. The recipient will examine how transcription factors STAT3 and JUNB, and the histone methyltransferase EZH2, establish and maintain...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $240,600 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate the combined immunomodulatory effects of macrolides and corticosteroids in hospitalized patients with community-acquired pneumonia. The study investigates how macrolide antibiotics and corticosteroids, often coadministered in community-acquired pneumonia treatment, affect inflammatory markers and clinical outcomes....
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $638,403 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the roles of group 2 innate lymphoid cells (ILC2s) in type 2 immunity and asthma. The project examines immunological mechanisms underlying airway inflammation in asthma patients, focusing on how ILC2s—which rapidly produce type 2 cytokines—regulate adaptive immune responses in the lungs and...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $100,228 on November 23, 2026, to develop and evaluate novel biostatistical methods for human microbiome metagenomic data analysis under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds two primary research aims. In Aim 1, the recipient will systematically evaluate widely used methods for analyzing longitudinal microbiome data—specifically mixed-effects models—and develop a simpler...